LAKE FOREST, Ill., Feb. 14, 2012 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today reported results for the fourth quarter and full year ended Dec. 31, 2011. For the fourth quarter of 2011, net sales were $1.0 billion, and adjusted* diluted earnings per share were $0.51. For full-year 2011, net sales were $4.1 billion, and adjusted* diluted earnings per share were $3.04. (Adjusted* measures exclude certain specified items as described later in this press release and the attached schedules.)
"While 2011 was a challenging year as a result of our quality transformation efforts, we met our revised financial expectations, generating over $4 billion in sales, and advanced our remediation efforts," said F. Michael Ball, chief executive officer. "We made significant progress on many fronts during the year, including the launch in the United States of two important oncolytic products and an anti-infective drug, as well as initiating the Phase III U.S. clinical program for our biosimilar erythropoietin. We remain firmly committed to reinforcing our foundation and instilling a culture of high quality throughout the organization, actions we believe will create a strong competitive advantage for Hospira and position us for sustainable, long-term growth and increased shareholder value."
